Cullinan Therapeutics (CGEM) Accumulated Depreciation (2020 - 2025)

Cullinan Therapeutics' Accumulated Depreciation history runs 6 years deep, the most recent figure standing at $969000.0 for Q4 2025.

• In Q4 2025, Accumulated Depreciation rose 47.26% year-over-year to $969000.0; the TTM figure through Dec 2025 stood at $969000.0 (up 47.26% YoY), while the FY2025 annual figure was $969000.0, up 47.26% from the prior year.
• Accumulated Depreciation for Q4 2025 stood at $969000.0, up from $658000.0 in the prior quarter.
• The five-year high for Accumulated Depreciation was $969000.0 in Q4 2025, with the low at $135000.0 in Q4 2022.
• The 5-year median for Accumulated Depreciation is $352000.0 (2023), against an average of $469200.0.
• The sharpest annual moves came in 2022 and 2023: Accumulated Depreciation plunged 41.81% in 2022, then surged 160.74% in 2023.
• Cullinan Therapeutics' Accumulated Depreciation stood at $232000.0 in 2021, then slumped by 41.81% to $135000.0 in 2022, then surged by 160.74% to $352000.0 in 2023, then jumped by 86.93% to $658000.0 in 2024, then jumped by 47.26% to $969000.0 in 2025.
• Business Quant data shows CGEM's Accumulated Depreciation at $969000.0 in Q4 2025, $658000.0 in Q4 2024, and $352000.0 in Q4 2023.